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Introduction
(R)-[11C]Verapamil (VPM) is a new positron emission
tomography (PET) tracer to measure P-glycoprotein (P-
gp)-mediated transport at the blood-brain barrier (BBB).
Owing to the lack of a suitable reference region in brain
that is devoid of P-gp, a metabolite-corrected arterial
input function is required for quantitative analysis of VPM
PET data [1]. The aim of this study was to compare metab-
olism of VPM in epilepsy patients and healthy volunteers.
Methods
Selected arterial blood samples from 9 patients, who
underwent VPM PET, were analyzed for radiolabeled
metabolites by a previously described combined solid-
phase extraction/HPLC assay [2].
Results
VPM metabolism was significantly faster in patients as
compared to healthy volunteers [1] (unchanged VPM at
60 min after injection: 26.1 ± 6.4 vs. 49.0 ± 13.4%, p <
0.05, t-test).
Conclusion
Faster metabolism of VPM in epilepsy patients may be
caused by CyP450 enzyme induction by antiepileptic
drugs. Based on these data caution is warranted when
using an averaged arterial input function derived from
healthy volunteers for the analysis of patient data. As radi-
olabeled metabolites of VPM are known to cross the BBB
[1], different kinetic modeling parameters obtained in
patients and healthy volunteers might be at least partly
attributed to different rates of tracer metabolism rather
than to differences in cerebral P-gp activity.
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